e598b2c1-abeb-4421-acf8-79fe3d507ef8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.400
- HEDGEHOG_SIGNALING+0.400
- INTERFERON_ALPHA_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- IL6_JAK_STAT3_SIGNALING+0.300
- PROTEIN_SECRETION+0.300
- TGF_BETA_SIGNALING+0.300
- ANDROGEN_RESPONSE+0.200
- IL2_STAT5_SIGNALING+0.200
- INFLAMMATORY_RESPONSE+0.200
Top 10 suppressed
- E2F_TARGETS-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- ANGIOGENESIS-0.300
- DNA_REPAIR-0.300
- G2M_CHECKPOINT-0.200
- APICAL_JUNCTION-0.100
- COAGULATION-0.100
- ESTROGEN_RESPONSE_LATE-0.100
- FATTY_ACID_METABOLISM-0.100
- GLYCOLYSIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 3e17c945-a810-4d82-af11-93debdee3f21 | — | — | 0.748 |
| 2 | TCGA-UY-A9PA-01A-11R-A38B-07 | — | — | 0.718 |
| 3 | SRR23303760 | — | — | 0.718 |
| 4 | TCGA-CQ-7063-01A-11R-2403-07 | — | — | 0.717 |
| 5 | f0e20c4e-ac0b-45e1-a53b-2de9a19843b1 | — | — | 0.715 |
| 6 | TCGA-97-7552-01A-11R-2039-07 | — | cohortA1 | 0.708 |
| 7 | 271ce4d2-844f-4515-be45-10712b3685c5 | — | — | 0.699 |
| 8 | TCGA-D8-A1JB-01A-11R-A13Q-07 | — | A | 0.676 |
| 9 | TCGA-AC-A2FB-01A-11R-A17B-07 | — | A | 0.675 |
| 10 | SRR23036897 | — | — | 0.674 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |